Finally, the first pan-cancer investigation of ISCA1 indicated that the factor was differently expressed between tumor and normal tissues, as well as a link between ISCA1 expression and BLCA clinical outcome. This evidence concerns the gene ISCA1 and bladder transitional cell carcinoma.